Předměty
Publikace
- Oncology The Immune Microenvironment in Prostate Cancer: A Comprehensive Review2025 | 1. lékařská fakulta, 2. lékařská fakulta, Fakulta tělesné výchovy a sportu
- Association of the combined parameters including the frequency of primary cilia, PD-L1, Smoothened protein, membranous I3-catenin and cytoplasmic I3-catenin expression with the outcome of patients with clear cell renal cell carcinoma2025 | 1. lékařská fakulta, 3. lékařská fakulta
- Fecal miRNA profiles in colorectal cancers with mucinous morphology2025 | 1. lékařská fakulta, Lékařská fakulta v Plzni
- Molecular Human Reproduction Bioenergetics of human spermatozoa in patients with testicular germ cell tumours2025 | 1. lékařská fakulta, Přírodovědecká fakulta
- Cancer Immunology, Immunotherapy Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)2025 | Lékařská fakulta v Plzni, Lékařská fakulta v Hradci Králové
- International Journal of Cancer Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial2025 | 1. lékařská fakulta
- Clinical & Experimental Metastasis Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2EV study2025 | Lékařská fakulta v Plzni
- Prostate Cancer Skeletal Muscle Loss During Treatment With Abiraterone in Patients With Metastatic Prostate Cancer2025 | 1. lékařská fakulta
- Cancer Immunology, Immunotherapy Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study2025 | Publikace bez příslušnosti k fakultě
- Targeted Oncology Relugolix in Combination with Androgen Receptor Pathway Inhibitors in the Treatment of Metastatic Prostate Cancer: A Clinical Perspective2025 | Publikace bez příslušnosti k fakultě
Loading network view...
